Acquired melanocytic naevi (AMN) are a well-known risk factor for the development of melanoma. Whereas previous studies have reviewed AMN distributions on individual body sites, the clinical distribution of AMN on the adult trunk has not been thoroughly investigated. We studied 40 participants with 1,282 naevi >5 mm, of which 781 were located on the trunk. Remarkably, 70% of these truncal naevi were located on the back and we produced a continuous mathematical description of decreasing naevus frequency moving dorsolaterally from the back midline. Furthermore we found that for both sexes the mean naevus size was larger on the front as well as on the lower trunk. This distinct pattern, whilst probably being unwritten knowledge (in the dermatology domain), has not been discussed before.

Keywords:
Naevus count, Acquired melanocytic naevi, Trunk, Body site, Distribution, Melanoma, Phenotype
1.
Hearing VJ, Leong PL: From Melanocytes to Melanoma: The Progression of Malignancy. Totowa, Humana Press, 2006.
2.
Gilbert SF: Developmental Biology, ed 6. Sunderland, Sinauer Associates, 2000.
3.
Hirobe T: How are proliferation and differentiation of melanocytes regulated? Pigment Cell Melanoma Res 2011;24:462-478.
4.
Zalaudek I, Ferrara G, Argenziano G: Dermoscopy insights into nevogenesis: ‘Abtropfung' versus ‘Hochsteigerung'. Arch Dermatol 2007;143:284.
5.
McClenahan P, Blake T, Douglas N, Gilmore S, Soyer HP: Quantifying the orientation of acquired melanocytic naevi on the back. Arch Dermatol 2012;148:857-859.
6.
Witt C, Krengel S: Clinical and epidemiological aspects of subtypes of melanocytic nevi (flat nevi, Miescher nevi, Unna nevi). Dermatol Online J 2010;16:1.
7.
Zalaudek I, Schmid K, Marghoob AA, Scope A, Manzo M, Moscarella E, Malvehy J, Puig S, Pellacani G, Thomas L, Catricalà C, Argenziano G: Frequency of dermoscopic nevus subtypes by age and body site: a cross-sectional study. Arch Dermatol 2011;147:663-670.
8.
Youl PH, Janda M, Aitken JF, Del Mar CB, Whiteman DC, Baade PD: Body-site distribution of skin cancer, pre-malignant and common benign pigmented lesions excised in general practice. Br J Dermatol 2011;165:35-43.
9.
Whiteman DC, Brown RM, Purdie DM, Hughes MC: Prevalence and anatomical distribution of naevi in young Queensland children. Int J Cancer 2003;106:930-933.
10.
Harrison SL, Bettner PG, MacLennan R: Body-site distribution of melanocytic nevi in young Australian children. Arch Dermatol 1999;135:47-52.
11.
Nicholls EM: Development and elimination of pigmented moles, and the anatomical distribution of primary malignant melanoma. Cancer 1973;32:191-195.
12.
Kelly JW, Holly EA, Shpall SN, Ahn DK: The distribution of melanocytic naevi in melanoma patients and control subjects. Australas J Dermatol 1989;30:1-8.
13.
Oliveria SA, Geller AC, Dusza SW, Marghoob AA, Sachs D, Weinstock MA, Buckminster M, Halpern AC: The Framingham school nevus study: a pilot study. Arch Dermatol 2004;140:545-551.
14.
Autier P, Boniol M, Severi G, Giles G, Cattaruzza MS, Luther H, Renard F, Grivegnée AR, Pedeux R, Doré JF; EPIMEL: The body site distribution of melanocytic naevi in 6-7 year old European children. Melanoma Res 2001;11:123-131.
15.
English DR, Armstrong BK: Melanocytic nevi in children. I. Anatomic sites and demographic and host factors. Am J Epidemiol 1994;139:390-401.
16.
Zemelman DV, Molina CP, Valenzuela CY, Honeyman MJ: Body distribution and density of acquired melanocytic nevi in adolescents of low socioeconomic status of Santiago, Chile. Rev Med Chil 2008;136:747-752.
17.
MacLennan R, Kelly JW, Rivers JK, Harrison SL: The Eastern Australian Childhood Nevus Study: site differences in density and size of melanocytic nevi in relation to latitude and phenotype. J Am Acad Dermatol 2003;48:367-375.
18.
Gallus S, Naldi L, Carli P, La Vecchia C; Italian Group for Epidemiologic Research in Dermatology (GISED): Nevus count on specific anatomic sites as a predictor of total body count: a survey of 3,406 children from Italy. Am J Epidemiol 2007;166:472-478.
19.
Oliveria SA, Satagopan JM, Geller AC, Dusza SW, Weinstock MA, Berwick M, Bishop M, Heneghan MK, Halpern AC: Study of Nevi in Children (SONIC): baseline findings and predictors of naevus count. Am J Epidemiol 2009;169:41-53.
20.
Green A, Siskind V, Hansen ME, Hanson L, Leech P: Melanocytic nevi in schoolchildren in Queensland. J Am Acad Dermatol 1989;20:1054-1060.
21.
Luther H, Altmeyer P, Garbe C, Ellwanger U, Jahn S, Hoffmann K, Segerling M: Increase of melanocytic nevus counts in children during 5 years of follow-up and analysis of associated factors. Arch Dermatol 1996;132:1473-1478.
22.
Whiteman DC, Brown RM, Purdie DM, Hughes MC: Melanocytic nevi in very young children: the role of phenotype, sun exposure, and sun protection. J Am Acad Dermatol 2005;52:40-47.
23.
Bauer J, Büttner P, Wiecker TS, Luther H, Garbe C: Risk factors of incident melanocytic nevi: a longitudinal study in a cohort of 1,232 young German children. Int J Cancer 2005;115:121-126.
24.
Aalborg J, Morelli JG, Byers TE, Mokrohisky ST, Crane LA: Effect of hair color and sun sensitivity on nevus counts in white children in Colorado. J Am Acad Dermatol 2010;63:430-439.
25.
Walter SD, Ashbolt R, Dwyer T, Marrett LD: Do larger people have more naevi? Naevi frequency versus naevus density. Int J Epidemiol 2000;29:1025-1030.
26.
Gallus S, Naldi L, Martin L, Martinelli M, La Vecchia C: Anthropometric measures and risk of cutaneous malignant melanoma: a case-control study from Italy. Melanoma Res 2006;16:83-87.
27.
Bauer J, Garbe C: Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment Cell Res 2003;16:297-306.
28.
Rinn JL, Wang JK, Allen N, Brugmann SA, Mikels AJ, Liu H, Ridky TW, Stadler HS, Nusse R, Helms JA, Chang HY: A dermal HOX transcriptional program regulates site-specific epidermal fate. Genes Dev 2008;22:303-307.
29.
Yamaguchi Y, Hearing VJ, Itami S, Yoshikawa K, Katayama I: Mesenchymal-epithelial interactions in the skin: aiming for site-specific tissue regeneration. J Dermatol Sci 2005;40:1-9.
30.
Australian Institute of Health and Welfare: Australia's Health 2012. 13 (AUS 156). Canberra, AIHW, 2012.
31.
Bulliard JL, De Weck D, Fisch T, Bordoni A, Levi F: Detailed site distribution of melanoma and sunlight exposure: aetiological patterns from a Swiss series. Ann Oncol 2007;18:789-794.
32.
Autier P, Severi G, Pedeux R, Cattaruzza MS, Boniol M, Grivegnée A, Doré JF; European Organisation for Research and Treatment of Cancer Melanoma Group: Number and size of naevi are influenced by differential sun exposure components: implications for the aetiology of cutaneous melanoma (Belgium, Germany, France, Italy). Cancer Causes Control 2003;14:453-459.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.